Reuters logo
Spectrum Pharma's blood cancer drug meets goal in mid-stage trial
December 21, 2012 / 12:45 PM / 5 years ago

Spectrum Pharma's blood cancer drug meets goal in mid-stage trial

(Reuters) - Spectrum Pharmaceuticals Inc said a mid-stage trial of its experimental blood cancer drug met the main goal of shrinking tumors.

The drug, belinostat, was tested in patients with relapsed/refractory peripheral T-Cell (PTCL) lymphoma, who have failed at least one therapy.

The biotechnology company said it expects to file a marketing application with U.S. health regulators by mid-2013, and expects a review date in 2014.

Belinostat was granted orphan-drug status and fast-track status by the U.S. Food and Drug Administration for PTCL.

Spectrum’s shares, which have fallen about 22 percent in the last year, closed at $11.30 on the Nasdaq on Thursday.

Reporting By Vrinda Manocha in Bangalore; Editing by Don Sebastian

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below